The Food and Drug Administration (FDA) has approved updated labeling for Cosentyx (secukinumab; Novartis) to include data regarding the use of secukinumab in the treatment of moderate to severe plaque psoriasis.
In the SCALP study, patients with moderate to severe psoriasis lesions of the scalp (n=102) were randomized to receive either Cosentyx 300 mg or placebo at Weeks 0, 1, 2, and 3, then every 4 weeks for 12 weeks.
Patients in the placebo group who did not demonstrate ≥90% improvement from baseline in the PSSI (Psoriasis Scalp Severity Index) score were switched to Cosentyx at Weeks 12, 13, 14, 15, 16, and 20.
The 12-week primary endpoint results found Cosentyx to be superior to placebo as indicated by the proportion of patients who achieved PSSI 90 response. In addition, a larger percentage of patients in the Cosentyx group achieved an IGA (Investigator’s Global Assessment) scalp only score of 0 or 1 (clear or almost clear) vs the placebo group (56.9% vs 5.9%, respectively).
Cosentyx, an interleukin-17A (IL-17A) antagonist, is approved to treat moderate to severe plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). IL-17A is a critical cytokine involved in the development of plaque psoriasis, PsA, and AS.
Cosentyx is available as 150 mg/mL solution for subcutaneous (SC) injection and as a lyophilized powder for SC injection after reconstitution in prefilled syringes, single-use vials, and as Sensoready pens.
Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis [press release]. Basel: Novartis; February 8, 2018. Accessed February 13, 2018.
This article originally appeared on MPR